NCT07197112View on ClinicalTrials.gov

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

December 1, 2027

Conditions

Acute Graft Versus Host Disease Grade II-IVAcute Graft vs Host Disease

Interventions

DRUG

Gecacitinib

Administer 50 mg twice daily for a minimum of 28 days.

All Listed Sponsors

lead

Ruijin Hospital

OTHER